{
  "source": "PA-Notification-Lotronex.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1060-14\nProgram Prior Authorization/Notification\nMedication Lotronex®* (alosetron)\nP&T Approval Date 5/2013, 5/2014, 5/2015, 4/2016, 10/2016, 10/2017, 10/2018, 10/2019,\n11/2020, 11/2021, 1/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nLotronex (alosetron) is indicated only for use in women with severe diarrhea-predominant irritable\nbowel syndrome (IBS) who have chronic IBS symptoms, had anatomic or biochemical\nabnormalities of the gastrointestinal (GI) tract excluded and have not responded adequately to\nconventional therapy.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Lotronex will be approved based on all of the following criteria:\na. Diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) with\nsymptoms for at least six months\n-AND-\nb. Patient was female at birth\n-AND-\nc. Has not responded adequately to conventional therapy (e.g., loperamide,\nantispasmodics)\n-AND-\nd. Anatomic or biochemical abnormalities of the GI tract have been excluded\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Lotronex will be approved based on documentation of positive clinical response to\nLotronex therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n* Brand Lotronex is typically excluded from coverage. Tried/failed criteria may be in place. Please\nrefer to plan specifics to determine coverage status\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Sup",
    "on\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Lotronex [package insert]. Roswell, Georgia: Sebela Pharmaceuticals; April 2019.\nProgram Prior Authorization/Notification- Lotronex\nChange Control\nDate Change\n5/2013 New Program\n5/2014 Clarified reauthorization criteria and increased reauthorization approval\nperiod. Removed age edit. Added requirement for exclusion of\nanatomic or biochemical abnormalities of GI tract.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n5/2015 Annual Review. No changes.\n4/2016 Annual Review. Added requirements for symptoms associated with\nIBS.\n10/2016 Added HCR gender dysphoria language.\n10/2017 Revised initial authorization criteria. Increased authorization to 6\nmonths. Revised reauthorization criteria.\n10/2018 Annual review. No changes.\n10/2019 Annual review. No changes.\n11/2020 Annual review. Updated references.\n11/2021 Annual review. Added requirements for exclusion of anatomic or\nbiochemical abnormalities of GI tract. Updated references.\n1/2023 Annual review. Added state mandate language.\n1/2024 Annual review. No changes.\n1/2025 Annual review. Updated initial authorization to 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}